Meeting
2023 ASCO Annual Meeting
Evaluating generalizability of practice-changing randomized clinical trials in non-small cell lung cancer using machine learning-based in-silico trials.
Authors
Xavier Orcutt
Chinle Comprehensive Health Care Facility, Chinle, AZ
Xavier Orcutt , Ronac Mamtani , Arjun Sondhi , Aaron B. Cohen , Ravi Bharat Parikh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9130)
DOI
10.1200/JCO.2023.41.16_suppl.9130
Abstract #
9130
Poster Bd #
118
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.
First Author: Melissa Lynne Johnson
Poster
2024 ASCO Annual Meeting
Survival and patient-reported outcomes of real-world patients with high-risk stage II and stage III colon cancer after 3 versus 6 months of adjuvant CAPOX.
First Author: Ingrid A. Franken
Poster
2024 ASCO Annual Meeting
Comparative analysis of pembrolizumab and cetuximab-based therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma: Real-world data.
First Author: Zahra Hamedi
Poster
2024 ASCO Annual Meeting
Randomized phase III study comparing suspension or continuation of PD-1 pathway blockade for patients with advanced non-small-cell lung cancer (SAVE study: JCOG1701).
First Author: Yasushi Goto